Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Singapore’s state-owned investment firm Temasek and Chinese internet tycoon Jack Ma-backed Yunfeng Capital have led a $75 million Series B into WuXi NextCODE.
The Abu Dhabi Investment Authority and Singapore’s GIC have bought a minority stake in PPD, valuing the CRO giant at more than $9 billion.
NCGS is expanding its business by relocating to a new corporate headquarters, bringing $10 million in investment and creating 80 new jobs.
Amid new approvals last year, drugmakers also suffered R&D setbacks, cut research staff, rejigged their operations and refocused their pipelines.
Takeda is nearing the final stages of a joint venture with PRA Health Sciences, the product of an expansion of their clinical development partnership in Japan…
A bipartisan bill that plans to allow a tax credit for expenses of contracted research—often done by CROs—has been introduced in the House of Representatives.
WuXi AppTec is seeking an IPO on China’s common stock market, a move that confirmed buzz that the CRO giant would re-enlist its businesses in three pieces.
Parexel has acquired contract medical affairs services provider The Medical Affairs Company as it looks to bolster its outsourced healthcare specialist…
PPD is opening a 24-bed clinical research unit in Las Vegas in support of its early drug development services.
WuXi AppTec, one of the largest CROs in China, has just acquired a Shanghai-based preclinical counterpart, HD Biosciences, building further on its core…